Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00370331 · OUTCOME

HR-QoL Instrument and Domain Scores From the FACIT-F Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment

RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag · Source last updated 2017-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Points on a scale (0-52)
Interval / dispersion
Standard Deviation
Time frame
Baseline, Week 6, Week 14, and Week 26/Early Withdrawal

What was measured

Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of chronic illness therapy fatigue (FACIT-F) questionnaire. Scores could range from 0 (worst possible) to 52 (best possible).

Analysis population: ITT Population

Groups in this outcome

Placebo

Matching placebo tablets taken once a day

Eltrombopag 50 mg QD

Eltrombopag 50 mg oral tablets taken once a day (QD)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo62
Eltrombopag 50 mg QD135

Reported measurements

Baseline
Values in Points on a scale (0-52) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo36.39.0Not reportedNot reportedNot reported
Eltrombopag 50 mg QD36.012.2Not reportedNot reportedNot reported
Week 6
Values in Points on a scale (0-52) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo38.38.2Not reportedNot reportedNot reported
Eltrombopag 50 mg QD39.29.7Not reportedNot reportedNot reported
Week 14
Values in Points on a scale (0-52) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo36.910.2Not reportedNot reportedNot reported
Eltrombopag 50 mg QD39.59.9Not reportedNot reportedNot reported
Week 26/Early Withdrawal
Values in Points on a scale (0-52) · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo37.011.3Not reportedNot reportedNot reported
Eltrombopag 50 mg QD39.210.1Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        9.0
        value
        36.3
      2. group Id
        OG001
        spread
        12.2
        value
        36.0
    title
    Baseline
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        8.2
        value
        38.3
      2. group Id
        OG001
        spread
        9.7
        value
        39.2
    title
    Week 6
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        10.2
        value
        36.9
      2. group Id
        OG001
        spread
        9.9
        value
        39.5
    title
    Week 14
  4. categories
    1. measurements
      1. group Id
        OG000
        spread
        11.3
        value
        37.0
      2. group Id
        OG001
        spread
        10.1
        value
        39.2
    title
    Week 26/Early Withdrawal
denoms
  1. counts
    1. group Id
      OG000
      value
      62
    2. group Id
      OG001
      value
      135
    units
    Participants
description
Health-related quality of life (HR-QoL) patient reported outcomes from the functional assessment of chronic illness therapy fatigue (FACIT-F) questionnaire. Scores could range from 0 (worst possible) to 52 (best possible).
dispersion Type
Standard Deviation
groups
  1. description
    Matching placebo tablets taken once a day
    id
    OG000
    title
    Placebo
  2. description
    Eltrombopag 50 mg oral tablets taken once a day (QD)
    id
    OG001
    title
    Eltrombopag 50 mg QD
param Type
MEAN
population Description
ITT Population
reporting Status
POSTED
time Frame
Baseline, Week 6, Week 14, and Week 26/Early Withdrawal
title
HR-QoL Instrument and Domain Scores From the FACIT-F Questionnaire at Baseline, Week 6, Week 14, and Week 26 or Early Discontinuation From Study Treatment
type
SECONDARY
unit Of Measure
Points on a scale (0-52)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice